Biophysical Fragment Screening of the β1-Adrenergic Receptor: Identification of High Affinity Arylpiperazine Leads Using Structure-Based Drug Design
暂无分享,去创建一个
Christopher G. Tate | David G. Myszka | Miles Congreve | Benjamin Tehan | M. Congreve | A. Doré | J. Errey | F. Marshall | C. Tate | R. Rich | D. Myszka | B. Tehan | T. Warne | M. Koglin | J. Christopher | Tony Warne | Andrew S. Doré | Fiona H. Marshall | Rebecca L. Rich | John A. Christopher | Jason Brown | James C. Errey | Markus Koglin | Jason L. Brown | A. S. Doré | Tony Warne
[1] S. Pridmore. What a Time , 2015 .
[2] Christopher G Tate,et al. The importance of interactions with helix 5 in determining the efficacy of β-adrenoceptor ligands. , 2013, Biochemical Society transactions.
[3] S. P. Andrews,et al. Stabilised G protein-coupled receptors in structure-based drug design: a case study with adenosine A2A receptor , 2013 .
[4] P. Hirth,et al. Vemurafenib: the first drug approved for BRAF-mutant cancer , 2012, Nature Reviews Drug Discovery.
[5] J. Shiloach,et al. Structure of the agonist-bound neurotensin receptor , 2012, Nature.
[6] Christopher G Tate,et al. A crystal clear solution for determining G-protein-coupled receptor structures. , 2012, Trends in biochemical sciences.
[7] Christopher G. Tate,et al. Crystal Structures of a Stabilized β1-Adrenoceptor Bound to the Biased Agonists Bucindolol and Carvedilol , 2012, Structure.
[8] Aashish Manglik,et al. Structure of the δ-opioid receptor bound to naltrindole , 2012, Nature.
[9] Brian K Shoichet,et al. Structure-based drug screening for G-protein-coupled receptors. , 2012, Trends in pharmacological sciences.
[10] Andrea Bortolato,et al. New insights from structural biology into the druggability of G protein-coupled receptors. , 2012, Trends in pharmacological sciences.
[11] Bryan L. Roth,et al. Structure of the Nociceptin/Orphanin FQ Receptor in Complex with a Peptide Mimetic , 2012, Nature.
[12] L. Pardo,et al. Crystal structure of the μ-opioid receptor bound to a morphinan antagonist , 2012, Nature.
[13] Albert C. Pan,et al. Structure and Dynamics of the M3 Muscarinic Acetylcholine Receptor , 2012, Nature.
[14] Hugh Rosen,et al. Crystal Structure of a Lipid G Protein–Coupled Receptor , 2012, Science.
[15] Bryan L. Roth,et al. Structure of the human kappa opioid receptor in complex with JDTic , 2012, Nature.
[16] A. Kruse,et al. Structure of the human M2 muscarinic acetylcholine receptor bound to an antagonist , 2011, Nature.
[17] R. Stevens,et al. Structure of the human k-opioid receptor in complex with JDTic , 2012 .
[18] Ron O. Dror,et al. High-resolution crystal structure of human Protease-Activated Receptor 1 bound to the antagonist vorapaxar , 2012, Nature.
[19] Daniel A Erlanson,et al. Introduction to fragment-based drug discovery. , 2012, Topics in current chemistry.
[20] R. Stevens,et al. Crystal structure-based virtual screening for fragment-like ligands of the human histamine H(1) receptor. , 2011, Journal of medicinal chemistry.
[21] Krzysztof Palczewski,et al. The Significance of G Protein-Coupled Receptor Crystallography for Drug Discovery , 2011, Pharmacological Reviews.
[22] Avner Schlessinger,et al. Ligand Discovery from a Dopamine D3 Receptor Homology Model and Crystal Structure , 2011, Nature chemical biology.
[23] Ruben Abagyan,et al. Structure of the human histamine H1 receptor complex with doxepin , 2011, Nature.
[24] Jonathan S. Mason,et al. Progress in Structure Based Drug Design for G Protein-Coupled Receptors , 2011, Journal of medicinal chemistry.
[25] Gebhard F. X. Schertler,et al. Two distinct conformations of helix 6 observed in antagonist-bound structures of a β1-adrenergic receptor , 2011, Proceedings of the National Academy of Sciences.
[26] R. Stevens,et al. Structure of an Agonist-Bound Human A2A Adenosine Receptor , 2011, Science.
[27] N. Pannu,et al. REFMAC5 for the refinement of macromolecular crystal structures , 2011, Acta crystallographica. Section D, Biological crystallography.
[28] J. Errey,et al. Biacore analysis with stabilized G-protein-coupled receptors. , 2011, Analytical biochemistry.
[29] Nathan Robertson,et al. The properties of thermostabilised G protein-coupled receptors (StaRs) and their use in drug discovery , 2011, Neuropharmacology.
[30] Christopher G. Tate,et al. The structural basis for agonist and partial agonist action on a β1-adrenergic receptor , 2010, Nature.
[31] S. Rasmussen,et al. Structure of a nanobody-stabilized active state of the β2 adrenoceptor , 2010, Nature.
[32] Gregg Siegal,et al. Fragment screening of stabilized G-protein-coupled receptors using biophysical methods. , 2011, Methods in enzymology.
[33] Schachter En. New beta2-adrenoceptor agonists for the treatment of chronic obstructive pulmonary disease , 2010 .
[34] R. Abagyan,et al. Structures of the CXCR4 Chemokine GPCR with Small-Molecule and Cyclic Peptide Antagonists , 2010, Science.
[35] Jonathan A. Javitch,et al. Structure of the Human Dopamine D3 Receptor in Complex with a D2/D3 Selective Antagonist , 2010, Science.
[36] R. Abagyan,et al. Conserved binding mode of human beta2 adrenergic receptor inverse agonists and antagonist revealed by X-ray crystallography. , 2010, Journal of the American Chemical Society.
[37] Brian K. Shoichet,et al. Structure-Based Discovery of A2A Adenosine Receptor Ligands , 2010, Journal of medicinal chemistry.
[38] P. Emsley,et al. Features and development of Coot , 2010, Acta crystallographica. Section D, Biological crystallography.
[39] B. A. Evans,et al. Ligand‐directed signalling at β‐adrenoceptors , 2010, British journal of pharmacology.
[40] James E. J. Mills,et al. High-Throughput Virtual Screening of Proteins Using GRID Molecular Interaction Fields , 2010, J. Chem. Inf. Model..
[41] Michèle N Schulz,et al. Recent progress in fragment-based lead discovery. , 2009, Current opinion in pharmacology.
[42] C. Tate,et al. Engineering G protein-coupled receptors to facilitate their structure determination. , 2009, Current opinion in structural biology.
[43] Gianni Chessari,et al. From fragment to clinical candidate--a historical perspective. , 2009, Drug discovery today.
[44] Christopher G Tate,et al. Development and crystallization of a minimal thermostabilised G protein-coupled receptor. , 2009, Protein expression and purification.
[45] Yoko Shibata,et al. Thermostabilisation of the neurotensin receptor NTS1 , 2009, Journal of molecular biology.
[46] Peter Kolb,et al. Structure-based discovery of β2-adrenergic receptor ligands , 2009, Proceedings of the National Academy of Sciences.
[47] Raymond C Stevens,et al. Discovery of new GPCR biology: one receptor structure at a time. , 2009, Structure.
[48] R. Stevens,et al. The 2.6 Angstrom Crystal Structure of a Human A2A Adenosine Receptor Bound to an Antagonist , 2008, Science.
[49] Yoko Shibata,et al. Co-evolving stability and conformational homogeneity of the human adenosine A2a receptor , 2008, Proceedings of the National Academy of Sciences.
[50] Gebhard F. X. Schertler,et al. Structure of a β1-adrenergic G-protein-coupled receptor , 2008, Nature.
[51] M. Crouch,et al. New strategies in drug discovery for GPCRs: high throughput detection of cellular ERK phosphorylation. , 2008, Combinatorial chemistry & high throughput screening.
[52] M. Congreve,et al. Recent developments in fragment-based drug discovery. , 2008, Journal of medicinal chemistry.
[53] Kam Y. J. Zhang,et al. Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity , 2008, Proceedings of the National Academy of Sciences.
[54] Yoko Shibata,et al. Conformational thermostabilization of the β1-adrenergic receptor in a detergent-resistant form , 2008, Proceedings of the National Academy of Sciences.
[55] Helgi B. Schiöth,et al. Structural diversity of G protein-coupled receptors and significance for drug discovery , 2008, Nature Reviews Drug Discovery.
[56] R. Stevens,et al. High-Resolution Crystal Structure of an Engineered Human β2-Adrenergic G Protein–Coupled Receptor , 2007, Science.
[57] M. Burghammer,et al. Crystal structure of the human β2 adrenergic G-protein-coupled receptor , 2007, Nature.
[58] P. Leeson,et al. The influence of drug-like concepts on decision-making in medicinal chemistry , 2007, Nature Reviews Drug Discovery.
[59] Y. Ohno,et al. Lurasidone (SM-13496), a novel atypical antipsychotic drug, reverses MK-801-induced impairment of learning and memory in the rat passive-avoidance test. , 2007, European journal of pharmacology.
[60] N. Blomberg,et al. An integrated approach to fragment-based lead generation: philosophy, strategy and case studies from AstraZeneca's drug discovery programmes. , 2007, Current topics in medicinal chemistry.
[61] Randy J. Read,et al. Phaser crystallographic software , 2007, Journal of applied crystallography.
[62] Jack Snoeyink,et al. Nucleic Acids Research Advance Access published April 22, 2007 MolProbity: all-atom contacts and structure validation for proteins and nucleic acids , 2007 .
[63] P. Evans,et al. Scaling and assessment of data quality. , 2006, Acta crystallographica. Section D, Biological crystallography.
[64] Q. Han,et al. Emerging concepts and therapeutic implications of beta-adrenergic receptor subtype signaling. , 2005, Pharmacology & therapeutics.
[65] Jillian G. Baker,et al. The selectivity of β‐adrenoceptor antagonists at the human β1, β2 and β3 adrenoceptors , 2005 .
[66] J. Peters,et al. Long-acting β2-agonists in the management of asthma exacerbations , 2005 .
[67] Andreas Bender,et al. Similarity Searching of Chemical Databases Using Atom Environment Descriptors (MOLPRINT 2D): Evaluation of Performance , 2004, J. Chem. Inf. Model..
[68] A. Hopkins,et al. Ligand efficiency: a useful metric for lead selection. , 2004, Drug discovery today.
[69] G. Schertler,et al. Expression and purification of truncated, non-glycosylated turkey beta-adrenergic receptors for crystallization. , 2003, Biochimica et biophysica acta.
[70] K. Palczewski,et al. Crystal Structure of Rhodopsin: A G‐Protein‐Coupled Receptor , 2002, Chembiochem : a European journal of chemical biology.
[71] Arthur A. Patchett,et al. Chapter 26. Privileged structures — An update , 2000 .
[72] A G Leslie,et al. Biological Crystallography Integration of Macromolecular Diffraction Data , 2022 .
[73] David R. Sibley,et al. Interactions of the Novel Antipsychotic Aripiprazole (OPC-14597) with Dopamine and Serotonin Receptor Subtypes , 1999, Neuropsychopharmacology.
[74] J. Ballesteros,et al. [19] Integrated methods for the construction of three-dimensional models and computational probing of structure-function relations in G protein-coupled receptors , 1995 .
[75] P. Goodford. A computational procedure for determining energetically favorable binding sites on biologically important macromolecules. , 1985, Journal of medicinal chemistry.
[76] Y. Cheng,et al. Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. , 1973, Biochemical pharmacology.